Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Routine +

Ventripoint and Ollie Hinkle Heart Foundation Partner to Expand Access to AI-Powered Heart Imaging for Children Living with Heart Disease

AI cardiac imaging startup scaling niche partnerships while navigating a critical $55k cash balance and negative working capital.

By The Northwire Desk — AI Analysis Jun 26, 2026 · 08:10 VPT · 0.105 VentriPoint Diagnostics Ltd.
Executive Summary
  • Ventripoint Diagnostics announced a strategic collaboration with the Ollie Hinkle Heart Foundation (OHHF) to expand access to its AI-powered VMS+ cardiac imaging platform for pediatric and congenital heart disease patients.
  • OHHF will provide initial financial support to deploy two VMS+ systems within its healthcare partner network.
  • The partnership integrates OHHF’s "Take Heart Collective Impact Model" to align families, clinicians, and innovators, aiming to reduce barriers to advanced cardiac imaging and support patient monitoring.
  • The VMS+ platform uses AI to provide MRI-level volumetric measurements from standard echocardiograms and holds regulatory approvals in the U.S., Europe, and Canada.
Material Impact
  • The deployment of two systems is operationally incremental and does not materially impact revenue or cash flow given the company's FY2025 revenue of $179,928 CAD.
  • The partnership serves as a strategic validation for the company's focus on underserved pediatric/congenital markets, aligning with its broader commercialization and hub-and-spoke distribution strategy.
  • No new capital is raised, and the financial support is limited to initial deployment costs. The news does not alter the company's immediate liquidity constraints or debt obligations.
VPT · Price
Company Overview
  • Ventripoint Diagnostics Ltd. is a medical technology company commercializing the VMS+™ platform, an AI-driven software that converts standard 2D echocardiograms into highly accurate 3D volumetric heart models.
  • The technology aims to provide MRI-level diagnostic accuracy at the point of care, reducing reliance on costly and time-consuming cardiac MRIs.
  • The company is transitioning from a product development phase to a commercial execution phase, utilizing a Device-as-a-Service (DaaS) subscription model to shorten sales cycles and generate recurring revenue.
  • Target markets include congenital heart disease, heart failure, pulmonary hypertension, and cardiotoxicity monitoring, with a focus on underserved, remote, and Indigenous communities through hub-and-spoke deployment models.
Read the original news release →

More from VentriPoint Diagnostics Ltd.

Jun 16, 2026 · 09:11

AI cardiac imaging startup scales commercial partnerships but remains cash-constrained and pre-revenue at scale.

Other Apr 28, 2026 · 08:00

Ventripoint Advances China Entry Amidst Persistent Dilution Concerns

Regulatory Apr 20, 2026 · 08:50

Ventripoint Wins Gold Edison Award But Cash Burn and Dilution Risks Persist

Other Apr 16, 2026 · 11:00

TSXV Venture Exchange Listed Cardiac Imaging Platform

M&A / Property Apr 01, 2026 · 22:50

Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group

M&A / Property Mar 27, 2026 · 10:15

MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

M&A / Property